172 related articles for article (PubMed ID: 12722742)
21. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
22. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
23. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
[TBL] [Abstract][Full Text] [Related]
24. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
Ali MM; Janic B; Babajani-Feremi A; Varma NR; Iskander AS; Anagli J; Arbab AS
PLoS One; 2010 Jan; 5(1):e8727. PubMed ID: 20090952
[TBL] [Abstract][Full Text] [Related]
25. Multiparametric characterization of response to anti-angiogenic therapy using USPIO contrast-enhanced MRI in combination with dynamic contrast-enhanced MRI.
Kim J; Kim E; Euceda LR; Meyer DE; Langseth K; Bathen TF; Moestue SA; Huuse EM
J Magn Reson Imaging; 2018 Jun; 47(6):1589-1600. PubMed ID: 29205621
[TBL] [Abstract][Full Text] [Related]
26. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC
Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179
[TBL] [Abstract][Full Text] [Related]
27. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report.
Brasch R; Turetschek K
Eur J Radiol; 2000 Jun; 34(3):148-55. PubMed ID: 10927157
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
[TBL] [Abstract][Full Text] [Related]
29. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
30. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
31. αvß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
Kazmierczak PM; Schneider M; Habereder T; Hirner-Eppeneder H; Eschbach RS; Moser M; Reiser MF; Lauber K; Nikolaou K; Cyran CC
Invest Radiol; 2016 Nov; 51(11):746-755. PubMed ID: 27082316
[TBL] [Abstract][Full Text] [Related]
32. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
33. Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.
Preda A; Wielopolski PA; Ten Hagen TL; van Vliet M; Veenland JF; Ambagtsheer G; van Tiel ST; Vogel MW; Eggermont AM; Krestin GP; van Dijke CF
MAGMA; 2004 Dec; 17(3-6):296-302. PubMed ID: 15480945
[TBL] [Abstract][Full Text] [Related]
34. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC
J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614
[TBL] [Abstract][Full Text] [Related]
35. Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Yazici YD; Kim S; Jasser SA; Wang Z; Carter KB; Bucana CD; Myers JN
Laryngoscope; 2005 Dec; 115(12):2249-55. PubMed ID: 16369175
[TBL] [Abstract][Full Text] [Related]
36. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.
Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA
Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815
[TBL] [Abstract][Full Text] [Related]
37. Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.
Jia WR; Chai WM; Tang L; Wang Y; Fei XC; Han BS; Chen M
Eur J Radiol; 2014 Jul; 83(7):1098-1105. PubMed ID: 24794865
[TBL] [Abstract][Full Text] [Related]
38. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
39. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors.
Turetschek K; Huber S; Helbich T; Floyd E; Tarlo KS; Roberts TP; Shames DM; Wendland MF; Brasch RC
Acad Radiol; 2002 May; 9 Suppl 1():S112-4. PubMed ID: 12019843
[No Abstract] [Full Text] [Related]
40. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
Turetschek K; Floyd E; Shames DM; Roberts TP; Preda A; Novikov V; Corot C; Carter WO; Brasch RC
Magn Reson Med; 2001 May; 45(5):880-6. PubMed ID: 11323815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
